The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is characterized by a widespread functional disturbance of the human brain. Fibrillar amyloid proteins are deposited inside neurons as neurofibrillary tangles and extracellularly as amyloid plaque cores and in blood vessels. The major protein subunit (A4) of the amyloid fibril of tangles, plaques and blood vessel deposits is an insoluble, highly aggregating small polypeptide of relative molecular mass 4,500. The same polypeptide is also deposited in the brains of aged individuals with trisomy 21 (Down's syndrome). We have argued previously that the A4 protein is of neuronal origin and is the cleavage product of a larger precursor protein. To identify this precursor, we have now isolated and sequenced an apparently full-length complementary DNA clone coding for the A4 polypeptide. The predicted precursor consists of 695 residues and contains features characteristic of glycosylated cell-surface receptors. This sequence, together with the localization of its gene on chromosome 21, suggests that the cerebral amyloid deposited in Alzheimer's disease and aged Down's syndrome is caused by aberrant catabolism of a cell-surface receptor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Molecular imaging studies such as those using amyloid positron emission tomography (PET) have shown that Aβ deposition reaches a plateau before brain atrophy can be identified from structural magnetic resonance imaging (MRI) and cognitive symptoms [15, 19].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [15]
In the citing paper
“All the mutant genes of hereditary, autosomal, and dominant familial AD, including amyloid precursor protein (APP), presenilin 1, and presenilin 2, encode the major proteins involved in amyloid metabolism [14–16].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [15]
In the citing paper
“Amyloid  protein (A), the principal protein in the senile plaques of Alzheimer's disease (AD), is an ϳ4 kDa secreted polypeptide”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Kang et al., 1987
In the citing paper
“APP isoforms are encoded by several alternatively spliced transcripts (Kang et al., 1987;K itaguchi et al., 1988;Ponte et al., 1988;Tanzi et al., 1988;Golde et al., 1990;Ko ¨nig et al., 1992).”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Kang et al., 1987
In the citing paper
“APP, first identified by Kang et al. [18], is a type I transmembrane protein with a long luminal N-terminal domain and a small cytoplasmic C-terminal tail [18,19].”
From Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations (2024) · cites this paper as [18]
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Rigby, P. W. J., Dieckmann, M., Rhodes, C., & Berg, P. (1977) · Journal of Molecular Biology · doi:10.1016/0022-2836(77)90052-3 · Cited by 11,401
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Thomas, P. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5201 · Cited by 8,156
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,751
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Self-citationLehrach, H., Diamond, D., Wozney, J. M., & Boedtker, H. (1977) · Biochemistry · doi:10.1021/bi00640a033 · Cited by 3,415
A gas-liquid solid phase peptide and protein sequenator.
Hewick, R. M., Hunkapiller, M. W., Hood, L. E., & Dreyer, W. J. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43377-7 · Cited by 2,218
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
A cellular gene encodes scrapie PrP 27-30 protein
Oesch, B., Westaway, D., Wälchli, M., McKinley, M. P., Kent, S. B. H., Aebersold, R., Barry, R. A., Tempst, P., Teplow, D. B., Hood, L. E., et al. (1985) · Cell · doi:10.1016/0092-8674(85)90333-2 · Cited by 1,513
Research works printed but not linked: 4
- Alzheimer, A. Allg. Z. Psychiat. 64, 146–148 (1907).
- Katzman, R. (ed.) Biological Aspects of Alzheimer's Disease (Banbury Report 15) (Cold Spring Harbor Laboratory, New York, 1983).
- Beyreuther, K. et al. in Discussions in Neuroscience Vol. 3 (eds Bignami, A., Bolis, L. & Gajdusek, D. C. 68–79 Fondation pour I'Étude du Système Nerveux, Geneva (1986).
- Goldgaber, D., Lerman, M. I., McBride, W. O., Sallow, V. & Gajdusek, D. C. Science (in the press).
Cited by
Items 601–700 of 1,071
Hureau, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.037 · Cited by 178
The interaction between Alzheimer amyloid β(1–40) peptide and ganglioside GM1‐containing membranes
Choo-Smith, L.-P., & Surewicz, W. K. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01504-9 · Cited by 178
Cataldo, A. M., Thayer, C. Y., Bird, E. D., Wheelock, T. R., & Nixon, R. A. (1990) · Brain Research · doi:10.1016/0006-8993(90)90456-l · Cited by 178
Hung, A. Y., Koo, E. H., Haass, C., & Selkoe, D. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9439 · Cited by 177
Monoamine neurons in aging and Alzheimer's disease
Palmer, A. M., & DeKosky, S. T. (1993) · Journal of Neural Transmission · doi:10.1007/bf01245229 · Cited by 178
The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective
Post, S. G. (1997) · JAMA · doi:10.1001/jama.277.10.832 · Cited by 176
Wang, R., Meschia, J. F., Cotter, R. J., & Sisodia, S. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55397-7 · Cited by 178
Otzen, D. E., Kristensen, O., & Oliveberg, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160086297 · Cited by 177
Beher, D., Clarke, E. E., Wrigley, J. D. J., Martin, A. C. L., Nadin, A., Churcher, I., & Shearman, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404937200 · Cited by 177
Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6641 · Cited by 177
Genetic dissection of Alzheimer disease, a heterogeneous disorder.
Schellenberg, G. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8552 · Cited by 177
Higgins, G. A., Lewis, D. A., Bahmanyar, S., Goldgaber, D., Gajdusek, D. C., Young, W. G., Morrison, J. H., & Wilson, M. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1297 · Cited by 177
Proteoglycan-mediated Inhibition of Aβ Proteolysis
Gupta-Bansal, R., Frederickson, R. C. A., & Brunden, K. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18666 · Cited by 176
De Strooper, B., Simons, M., Multhaup, G., Van Leuven, F., Beyreuther, K., & Dotti, C. G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00176.x · Cited by 174
“The PA4-peptide sequence -is located at the junction between the integral membrane domain and the extracellular domain of APP and is 39- 43 amino acids long (Kang et al., 1987).”
BackgroundSelf-citationPeripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini, L., Racchi, M., Binetti, G., Trabucchi, M., Solerte, S. B., Alkon, D., Etcheberrigaray, R., Gibson, G., Blass, J., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 175
“Via packaging in secretory vesicles (3), APP can travel to the plasma membrane (4); during this passage, APP can be cleaved either in the vesicle or at the plasma membrane by a secretase and then release (5) soluble sAPP into the extracellular compartment.”
BackgroundGene Dosage of the Amyloid β Precursor Protein in Alzheimer's Disease
Podlisny, M. B., Lee, G., & Selkoe, D. J. (1987) · Science · doi:10.1126/science.2960019 · Cited by 175
Ambroggio, E. E., Kim, D. H., Separovic, F., Barrow, C. J., Barnham, K. J., Bagatolli, L. A., & Fidelio, G. D. (2005) · Biophysical Journal · doi:10.1529/biophysj.104.055582 · Cited by 175
“This peptide is the product of the proteolytic cleavage of the Amyloid Precursor Protein (Kang et al., 1987; Selkoe, 1993).”
BackgroundTheoretical models of the ion channel structure of amyloid beta-protein
Durell, S. R., Guy, H. R., Arispe, N., Rojas, E., & Pollard, H. B. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80717-9 · Cited by 175
Mesulam, M. ‐., Geula, C., & Asuncion Morán, M. (1987) · Annals of Neurology · doi:10.1002/ana.410220603 · Cited by 175
A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor
Miyazaki, K., Hasegawa, M., Funahashi, K., & Umeda, M. (1993) · Nature · doi:10.1038/362839a0 · Cited by 175
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
“…1980s, firmly demonstrating b-amyloid as the main component of SPs and hyper-phosphorylated tau as the main component of NFTs (Glenner and Wong, 1984a,b; Masters et al., 1985; Grundke-Iqbal et al., 1986; Iqbal et al., 1986; Kang et al., 1987; Goedert et al., 1988, 1989; Delacourte et al., 1999).”
BackgroundIntegrated Analysis of the Cerebrospinal Fluid Peptidome and Proteome
Zougman, A., Pilch, B., Podtelejnikov, A., Kiehntopf, M., Schnabel, C., Kumar, C., & Mann, M. (2008) · Journal of Proteome Research · doi:10.1021/pr070501k · Cited by 174
Rastogi, S., Sharma, V., Bharti, P. S., Rani, K., Modi, G. P., Nikolajeff, F., & Kumar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010440 · Cited by 174
Tissue transglutaminase: a possible role in neurodegenerative diseases
Lesort, M., Tucholski, J., Miller, M. L., & Johnson, G. V. W. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00052-0 · Cited by 173
Neuronal and microglial involvement in beta-amyloid protein deposition in Alzheimer's disease.
Cras, P. P., Kawai, M., Siedlak, S. L., Mulvihill, P., Gambetti, P. L., Lowery, D. E., Gonzalez‐DeWhitt, P. A., Greenberg, B., & Perry, G. L. (1990) · Europe PMC (PubMed Central) · Cited by 184
Cotman, S. L., Halfter, W., & Cole, G. J. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0816 · Cited by 173
Prostaglandins and other lipid mediators in Alzheimer’s disease
Bazan, N. G., Colangelo, V., & Lukiw, W. J. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00031-x · Cited by 173
Rozemuller, J. M., Eikelenboom, P., Pals, S. T., & Stam, F. C. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90547-8 · Cited by 173
Kohnken, R., Buerger, K., Zinkowski, R., Miller, C., Kerkman, D., DeBernardis, J., Shen, J., Möller, H.-J., Davies, P., & Hampel, H. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173
Alzheimer .beta.-Amyloid Peptide 25-35: Electrostatic Interactions with Phospholipid Membranes
Terzi, E., Hoelzemann, G., & Seelig, J. (1994) · Biochemistry · doi:10.1021/bi00189a051 · Cited by 173
Dela�re, P., Duyckaerts, C., He, Y., Piette, F., & Hauw, J. J. (1991) · Acta Neuropathologica · doi:10.1007/bf00305876 · Cited by 175
“[mmunocytochemistry was performed with a rabbit antiserum raised against a synthetic peptide corresponding to the 42 residues [23] of the full length sequence of the flA4 protein (a gift of K.”
MethodBayer, T. A., Wirths, O., Majtényi, K., Hartmann, T., Multhaup, G., Beyreuther, K., & Czech, C. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00376.x · Cited by 173
Self-citationDegeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor
Yoshikawa, K., Aizawa, T., & Hayashi, Y. (1992) · Nature · doi:10.1038/359064a0 · Cited by 173
Selkoe, D., Mandelkow, E., & Holtzman, D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011460 · Cited by 173
“The cloning of the amyloid b-protein precursor in 1987 and discoveries of its diseasecausing mutations in 1990 and 1991 brought the field squarely into the era of molecular genetics and protein chemistry (Kang et al. 1987; Levy et al. 1990; Goate et al. 1991).”
BackgroundModifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease
Wang, X., Zhou, X., Li, G., Zhang, Y., Wu, Y., & Song, W. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00294 · Cited by 172
Goedert, M. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0466 · Cited by 172
“Although some staining for hyperphosphorylated tau has been described in nerve cell processes around Ab deposits in transgenic mice expressing mutated APP, no somatodendritic staining of hyperphosphorylated tau was observed in these mice.”
BackgroundInfluentialWeidemann, A., Paliga, K., Dürrwang, U., Reinhard, F. B. M., Schuckert, O., Evin, G., & Masters, C. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.9.5823 · Cited by 172
Self-citationInteractions between APP secretases and inflammatory mediators
Sastre, M., Walter, J., & Gentleman, S. M. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-25 · Cited by 171
Kaminski Schierle, G. S., van de Linde, S., Erdelyi, M., Esbjörner, E. K., Klein, T., Rees, E., Bertoncini, C. W., Dobson, C. M., Sauer, M., & Kaminski, C. F. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201651w · Cited by 171
The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer’s Disease
Rudy, C. C., Hunsberger, H. C., Weitzner, D. S., & Reed, M. N. (2015) · Aging and disease · doi:10.14336/ad.2014.0423 · Cited by 171
“Beta-amyloid (Aβ) has long been implicated in the pathogenesis of AD [109-113].”
BackgroundBiogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
Beher, D., Hesse, L., Masters, C. L., & Multhaup, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1613 · Cited by 170
Self-citationLorent, K., Overbergh, L., Moechars, D., de Strooper, B., van Leuven, F., & van den Berghe, H. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00555-j · Cited by 170
Roßner, S., Sastre, M., Bourne, K., & Lichtenthaler, S. F. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.06.001 · Cited by 169
Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization
Arendt, T. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00516-9 · Cited by 169
“It is the objective of the present paper to summarize evidence that it might be the disturbance of the structural brain self-organization which, based on both genetic and epigenetic information, constantly ªcreatesº and ªrecreatesº the brain throughout life, that is the defect that underlies AD.”
BackgroundChronic Inflammation and Amyloidogenesis in Alzheimer's Disease -- Role of Spirochetes1
Miklossy, J. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13404 · Cited by 168
“expressed in a variety of tissues [41].”
The genes associated with early-onset Alzheimer’s disease
Dai, M.-H., Zheng, H., Zeng, L.-D., & Zhang, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.23738 · Cited by 167
“APP proteins range from 365 to 770 amino acids due to different splicing isoforms [9, 19].”
Background?-amyloid Ca2+-channel hypothesis for neuronal death in Alzheimer Disease
Arispe, N., Pollard, H. B., & Rojas, E. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00926750 · Cited by 169
“Although the ultimate cause of neuronal death in AD remains to be elucidated, the discovery that major component of brain plaques is a 38-~2 residue peptide termed amyloid 13-protein [2, 3, 9 ] suggested the possibility that the amyloid ~-proteinsper se could be the causal factor in neuronal death [10].”
BackgroundRegulated Formation of Golgi Secretory Vesicles Containing Alzheimer β-Amyloid Precursor Protein
Xu, H., Greengard, P., & Gandy, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23243 · Cited by 169
“Signal transduction via protein phosphorylation governs the relative utilization of competing pathways for the metabolism of the b-amyloid precursor protein (b-APP) (Kang et al., 1987), the type 1 integral glycoprotein from which Ab is derived by proteolytic processing.”
BackgroundMechanism of Cerebral β-Amyloid Angiopathy: Murine and Cellular Models
Herzig, M. C., Nostrand, W. E., & Jucker, M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00560.x · Cited by 169
“44 Mechanism of Cerebral β-Amyloid Angiopathy Formation: Murine and Cellular Models—Herzig et al that neurons are the main source of APP and Aβ in brain (4, 64, 100).”
Background(1994) · PubMed Central · Cited by 169
Senile plaques in temporal lobe epilepsy
Mackenzie, I. R. A., & Miller, L. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00294177 · Cited by 168
“~A4 is an -40-amino acid protein derived from the larger amyloid precursor protein (APP) [20, 24, 25, 45, 55] which is normally expressed in a variety of tissues, including the brain [8, 18, 24, 38, 49, 65].”
BackgroundDisulfide bonds and thermal stability in T4 lysozyme.
Wetzel, R., Perry, L. J., Baase, W. A., & Becktel, W. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.401 · Cited by 168
The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide
Storey, & Cappai (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00164.x · Cited by 169
Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167
Giovannelli, L., Casamenti, F., Scali, C., Bartolini, L., & Pepeu, G. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00610-h · Cited by 167
Das, S., & Potter, H. (1995) · Neuron · doi:10.1016/0896-6273(95)90300-3 · Cited by 167
MATTSON, M. P. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44401.x · Cited by 166
Subcellular Topography of Neuronal Aβ Peptide in APPxPS1 Transgenic Mice
Langui, D., Girardot, N., El Hachimi, K. H., Allinquant, B., Blanchard, V., Pradier, L., & Duyckaerts, C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63405-0 · Cited by 165
Bellingham, S. A., Lahiri, D. K., Maloney, B., La Fontaine, S., Multhaup, G., & Camakaris, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400805200 · Cited by 164
Self-citationKaminsky, Y. G., Marlatt, M. W., Smith, M. A., & Kosenko, E. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.005 · Cited by 165
Zhuang, W., Hayashi, T., & Mukamel, S. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802644 · Cited by 165
The Molecular Basis of Copper Homeostasis Copper-Related Disorders
Llanos, R. M., & Mercer, J. F. B. (2002) · DNA and Cell Biology · doi:10.1089/104454902753759681 · Cited by 165
“APP has been shown to reduce Cu(II) to Cu(I), which can form reactive hydroxyl radicals (Multhaup et al. , 1996).”
InfluentialSipe, J. D., & Cohen, A. S. (1994) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369409084679 · Cited by 165
Zhou, Z.-D., Chan, C. H.-S., Ma, Q.-H., Xu, X.-H., Xiao, Z.-C., & Tan, E.-K. (2011) · Cell Adhesion & Migration · doi:10.4161/cam.5.4.16986 · Cited by 162
Alzheimer's disease β‐secretase BACE1 is not a neuron‐specific enzyme
Roßner, S., Lange‐Dohna, C., Zeitschel, U., & Perez‐Polo, J. R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02857.x · Cited by 163
“The major component of senile plaques are b-amyloid peptides, which are derived by proteolytical processing of the amyloid precursor protein (APP; Kang et al. 1987; Tanzi et al. 1987; Weidemann et al. 1989; see Fig.”
BackgroundMolecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression
Andronie-Cioara, F. L., Ardelean, A. I., Nistor-Cseppento, C. D., Jurcau, A., Jurcau, M. C., Pascalau, N., & Marcu, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031869 · Cited by 164
Pellegrini, L., Passer, B. J., Tabaton, M., Ganjei, J. K., & D'Adamio, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21011 · Cited by 139
Flood, J. F., Morley, J. E., & Roberts, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3363 · Cited by 164
Crimins, J. L., Pooler, A., Polydoro, M., Luebke, J. I., & Spires-Jones, T. L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.002 · Cited by 163
Lidström, A.-M., Bogdanovic, N., Hesse, C., Volkman, I., Davidsson, P., & Blennow, K. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6892 · Cited by 163
Prehn, J. H., Bindokas, V. P., Jordán, J., Galindo, M. F., Ghadge, G. D., Roos, R. P., Boise, L. H., Thompson, C. B., Krajewski, S., Reed, J. C., et al. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08714-0 · Cited by 163
Amyloid-β Peptide Disruption of Lipid Membranes and the Effect of Metal Ions
Lau, T.-L., Ambroggio, E. E., Tew, D. J., Cappai, R., Masters, C. L., Fidelio, G. D., Barnham, K. J., & Separovic, F. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.091 · Cited by 160
Self-citation?-Amyloid formation by myocytes of leptomeningeal vessels
Wisniewski, H. M., & Wegiel, J. (1994) · Acta Neuropathologica · doi:10.1007/bf00296738 · Cited by 162
“erating neurons, and astrocytes express ~PP [4, 9, 17, 18, 21, 29, 36, 40, 44, 46].”
Amyloidosis: a final common pathway for protein deposition in tissues
Stone, M. (1990) · Blood · doi:10.1182/blood.v75.3.531.531 · Cited by 162
Turner, R. S., Suzuki, N., Chyung, A. S. C., Younkin, S. G., & Lee, V. M.-Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8966 · Cited by 161
Intramembrane proteolysis by presenilins
Steiner, H., & Haass, C. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043065 · Cited by 161
“The βAPP protein is a ubiquitously expressed type I transmembrane domain protein, which is encoded by a gene located on chromosome 21 (Ref”
BackgroundSandbrink, R., Masters, C. L., & Beyreuther, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42286-1 · Cited by 162
Self-citationAlzheimer's disease and post-operative cognitive dysfunction
Xie, Z., & Tanzi, R. E. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.01.014 · Cited by 159
Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 159
“APP AND THE GENERATION OF Aβ THE APP FAMILY OF PROTEINS Amyloid precursor protein is a ubiquitously expressed type I integral transmembrane protein consisting of a large ectodomain, one single transmembrane domain, and a short intracellular tail (Kang et al., 1987; Dyrks et al., 1988).”
BackgroundAmyloidogenicity of rodent and human βA4 sequences
Dyrks, T., Dyrks, E., L. Masters, C., & Beyreuther, K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81399-k · Cited by 160
Self-citationThe nanometer-scale structure of amyloid-Β visualized by atomic force microscopy
Stine, W. B., Snyder, S. W., Ladror, U. S., Wade, W. S., Miller, M. F., Perun, T. J., Holzman, T. F., & Krafft, G. A. (1996) · Journal of Protein Chemistry · doi:10.1007/bf01887400 · Cited by 159
Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets
Evin, G., Zhu, A., Holsinger, R. M. D., Masters, C. L., & Li, Q. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10745 · Cited by 158
“A is a 4-kDa proteolytic fragment derived from the type I integral membrane protein amyloid precursor protein (APP) (Kang et al., 1987).”
BackgroundSelf-citationOxidative energy metabolism in Alzheimer brain: Studies in early-onset and late-onset cases
Hoyer, S. (1992) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159971 · Cited by 159
Kumar-Singh, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2589 · Cited by 158
Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain
Lütjohann, D., Brzezinka, A., Barth, E., Abramowski, D., Staufenbiel, M., von Bergmann, K., Beyreuther, K., Multhaup, G., & Bayer, T. A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200071-jlr200 · Cited by 158
“The amyloid deposits in AD brains are aggregates of the 40- to 42-residue A peptides (7, 8), originating from the large precursor protein APP (9, 10).”
Self-citationWalton, J. R., & Wang, M.-X. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.07.027 · Cited by 158
Down syndrome and Alzheimer's disease: A link between development and aging
Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 158
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 177
Ligand-dependent G Protein Coupling Function of Amyloid Transmembrane Precursor
Okamoto, T., Takeda, S., Murayama, Y., Ogata, E., & Nishimoto, I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.9.4205 · Cited by 158
ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site
Hussain, I., Powell, D. J., Howlett, D. R., Chapman, G. A., Gilmour, L., Murdock, P. R., Tew, D. G., Meek, T. D., Chapman, C., Schneider, K., et al. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0884 · Cited by 158
Regulated secretion of beta-amyloid precursor protein in rat brain
Farber, S., Nitsch, R., Schulz, J., & Wurtman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07442.1995 · Cited by 158
Guénette, S. Y., Chen, J., Jondro, P. D., & Tanzi, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10832 · Cited by 158
Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer’s disease
Gupta, A., & Iadecola, C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00115 · Cited by 157
“With the identification in the 1980’s of amyloid-β peptide (Aβ) as the main constituent of amyloid deposits in the cerebral vasculature (amyloid angiopathy) and in the brain parenchyma (amyloid plaque) in AD (Glenner and Wong, 1984; Kang et al., 1987), the emphasis shifted towards AD neuropathology as the major cause…”
BackgroundEndogenous Proteins Controlling Amyloid β-Peptide Polymerization
Bohrmann, B., Tjernberg, L., Kuner, P., Poli, S., Levet-Trafit, B., Näslund, J., Richards, G., Huber, W., Döbeli, H., & Nordstedt, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.15990 · Cited by 156
G-CSF rescues the memory impairment of animal models of Alzheimer's disease
Tsai, K.-J., Tsai, Y.-C., & Shen, C.-K. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062481 · Cited by 155
“β-Amyloid (Aβ), which is the major extracellular component of the senile plaques, is generated from cleavage of the amyloid precursor protein, a transmembrane protein, to an amyloidogenic end product (3).”
BackgroundTanaka, S., Shiojiri, S., Takahashi, Y., Kitaguchi, N., Ito, H., Kameyama, M., Kimura, J., Nakamura, S., & Ueda, K. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92760-5 · Cited by 207
Murphy, M. P., Hickman, L. J., Eckman, C. B., Uljon, S. N., Wang, R., & Golde, T. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11914 · Cited by 157
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 158
Ikezu, T., Trapp, B. D., Song, K. S., Schlegel, A., Lisanti, M. P., & Okamoto, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10485 · Cited by 157
Metadata
- Authors
- Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B.
- Affiliations
- University of Cologne (DE)
- Venue
- Nature
- Published
- 1987-02
- Volume
- 325
- Issue
- 6106
- Pages
- 733-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2081881251
- Cited by
- 4,619
- References
- 26
- Citations by year
- 2026: 38 · 2025: 58 · 2024: 63 · 2023: 71 · 2022: 54 · 2021: 79 · 2020: 82 · 2019: 76 · 2018: 76 · 2017: 98 · 2016: 111 · 2015: 90 · 2014: 97 · 2013: 119 · 2012: 126
- FWCI
- 164.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid precursor protein, cell surface receptors, Down syndrome, amyloid plaques, neurofibrillary tangles, chromosome 21, cDNA cloning, protein sequences
- MeSH terms
- Alzheimer Disease, Amyloid, Base Sequence, Brain, Brain Chemistry, Chromosomes, Human, Pair 21, DNA, Down Syndrome, Fetus, Humans, Neurofibrils, Nucleic Acid Hybridization, Protein Precursors, Protein Processing, Post-Translational, RNA, Messenger, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.